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The prognostic significance of microalbuminuria in insulin-dependent
diabetes meltitus: A twenty-three year follow-up study. A cohort of 63
Type 1 insulin-dependent diabetic patients were first characterized for
overnight urinary albumin excretion rate (AER) in 1967. In 1981, seven
out of eight (87%) patients with initial AER  30 140 g/min
(microalbuminuria) developed clinical proteinuria compared to only 2
out of 55 (4%) patients with initial AER < 30 g/min. The same cohort
of patients was reassessed in 1990 after a total follow-up period of 23
years. The aim was to investigate the role of microalbuminuria in the
prediction of total/cardiovascular mortality and the development of
renal failure, in addition to clinical proteinuria. The initially microalbu-
minuric patients had a significantly higher risk of developing not only
clinical proteinuria (relative risk 9.3, 95% Cl. 1.36 to 3.10, P < 0.05),
but also of dying from a cardiovascular cause (relative risk 2.94, 95%
CI. 1.18 to 7.34, P <0.05). The rate of progression to renal failure was
higher but not significantly so in the microalbuminuric (2 of 8) compared
to the normoalbumjnuric (4 of 53) group (relative risk 3.31, 95% C.l.
0.72 to 15.24, NS). In insulin-dependent diabetic patients microalbumi-
nuria is a powerful predictor of clinically overt diabetic renal disease as
well as cardiovascular mortality.
Diabetic nephropathy develops in approximately 30% of
insulin-dependent diabetic patients [1, 2] and carries a substan-
tially increased risk of early mortality from renal failure and
cardiovascular disease [3, 4]. In 1982, we reported that insulin-
dependent diabetic patients (IDDM) at risk of clinical nephrop-
athy, as indicted by persistent proteinuria, could be identified at
an early stage by detecting small increases of albumin excretion
in the urine, a phenomenon named microalbuminuria [5]. This
14-year longitudinal study was confirmed by shorter term
studies and microalbuminuria became established as a marker
of diabetic renal disease [6—81. In non-insulin-dependent dia-
betic patients microalbuminuria proved predictive not simply of
persistent proteinuria but also of early cardiovascular mortality
[9—131. There are suggestions that this too may apply to the
general population [13, 14]. In IDDM patients no study has
assessed the long-term predictive power of microalbuminuria
for end-stage renal failure or mortality and objections have been
raised as to the reliability of using urinary albumin excretion as
a predictor of risk of progressive renal disease [15, 16]. Because
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of the importance of relating relative small changes in urinary
albumin excretion to clear clinical outcome, we have analyzed
renal and survival status in our original cohort of IDDM with
and without microalbuminuria 23 years after the initial obser-
vation.
Methods
Patients
Overnight urinary albumin excretion rate (AER), arterial
blood pressure and serum creatinine were initially measured in
1966 to 1967 in a cohort of 63 IDDM patients below the age of
60 years. Fourteen years later seven of the eight patients with
initial AER above 30 Jig/mm (geometric mean 68.5; range 39 to
140 Jig/mm) had developed clinical proteinuria, of whom three
had died (1 proteinuric from renal failure, 2 from cardiovascular
disease) [5]. By contrast only two of the 55 patients with initial
AER below 30 p.g/min (geometric mean 4.77; range 0.2 to 21.8
Jig/mm) had become persistently proteinuric (3.6 vs. 87.5%, P
< 0.001) and there were five deaths (1 of renal failure, 1 with
carcinoma of the bronchus, 3 of cardiovascular disease; 9.1 vs.
37.5%, NS). We defined microalbuminurja as an AER between
30 to 140 Jig/mm inclusive, and suggested that excretion rates
within this range gave approximately 20-fold increased risk of
progression to persistent proteinuria.
Information on life/death status, causes of death, AER, blood
pressure and serum creatinine was sought again in 1990 for the
55 patients still alive in 1981, Relevant information on dead
patients was obtained from death certificates through the Office
of Population, Censuses and Surveys and whenever possible
from hospital records. A questionnaire for details of the pa-
tient's renal status before death was sent to the last attending
physician when known. All living patients were invited for a
repeat assessment. The patients no longer attending Guy's
Hospital Diabetic Clinic were contacted through their family
doctor or the regional Family Practitioner Committee, Patients
were instructed to collect a timed overnight urine specimen and
asked to attend a metabolic ward for measurements of serum
creatinine (Jaffé reaction rate method, Hitachi autoanalyzer,
BLC, Lewes, UK) and sitting blood pressure (phase I & V)
which was taken after five minutes rest to the nearest 2 mm Hg
using a standard mercury sphygmonsanometer. Urine was
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Table 1. Clinical characteristics of the 63 insulin-dependent diabetic
patients first assessed for albumin excretion rate in 1967
Baseline
characteristics
Initial AER in 1967
AER < 30
gImin
AER  30 140
g/min
No. of subjects (M, F)
AER /sg/,nin
Ageyears
Duration of diabetes
55 (36, 19)
4.77 (0.4—21.8)
39.2± 1.7
8.8 1.0
8 (5, 3)
68.5 (39.0—140)
41.4± 1.7
14.1 2.9
years
Patients are divided into 2 groups with microalbuminuria (initial AER
 30  140 jsg/min) and normoalbuminuria (initial AER < 30 jsg/min).
checked for sterility and the use of antihypertensive medication
was noted. Hospital notes were examined in each case for any
record of quantitative or semi-quantitative (Albustix test) mea-
surements of albuminuria since 1981. Urinary albumin concen-
tration was measured by radioimmunoassay [16], using a
method comparable to that used in 1967 and 1982. A system of
quality controls has been consistently carried through all albu-
min assays in our laboratory to ensure reproducibility of results
over time.
The diagnosis of renal failure was made if reported in the
death certificate or, in living patients when elevated serum
creatinine (Sr > 150 smol/liter) was associated with elevated
albumin excretion (AER  30 sg/min) or documented persis-
tently positive Albustix tests when quantitative measurements
of urinary albumin excretion were not available.
Statistical analysis
Parametric data were reported as mean standard error.
Albumin excretion rates were reported as geometric means and
ranges where appropriate. Student's t-test was used to compare
parametric variables. Relative risks and variance were derived
from contingency tables and 95% confidence intervals were
estimated using the method of Katz. A 95% confidence interval
which does not contain unity or a P value of < 0,05 is
considered significant. Stepwise logistic regression analysis was
used for calculation of age and duration of diabetes adjusted
effect of microalbuminuria on cardiovascular mortality.
Results
In 1990, two male patients aged 34 and 52 years in 1967 were
not traceable. The former was known to have emigrated since
1981, the latter was not currently registered with any general
practitioner in the U.K. Both of them were normoalbuminuric
in 1967 and 1981 and neither had been registered dead in the
U.K. since 1981. Information was thus obtained on 53 patients:
14 had died since 1982 and all the other 41 were reassessed.
Patients were classified according to their initial AER values in
1967 into either microalbuminuric (AER  30 .tg/min) or
normoalbuminuric (AER < 30 g/min) groups (Table 1).
The clinical outcome of the microalbuminuric patients is
diagrammatically represented in Figure 1. Of the five microal-
buminuric patients alive in 1981, two more had died, one at age
52 years from acute myocardial infarction at home with a last
recorded AER of 522 Lg/min. Serum creatinine in this patient
shortly before death was unavailable. The other patient died
from congestive cardiac failure at age 62 with a last recorded
Table 2. Clinical outcome of 61 of the 63 insulin-dependent di
patients after 23 year follow-up
abetic
Initial AER in 1967
AER < 30 AER  30 
g/min sg/min
140
Proteinuria 5/53 (9.4%) 7/8 (87.5%)
Renal failure 4/53 (7.5%) 2/8 (25%)
Total mortality 17/53 (32%) 5/8 (62.5%)
Non-cardiovascular deaths 8/53 (15.1%) 1/8 (12.5%)
Cardiovascular deaths 9/53 (17%) 4/8 (50%)
Age at death years 66.6 2.8 58.2 2.5
Duration of diabetes at 33.2 4.2 29.9 1.2
death years
Patients were divided into the microalbuminuric group (initial AER 
30  140 g/min) and normoalbuminuric group (initial AER < 30
rg/min).
Two patients of the original 55 normoalbuminuric patients who were
not contactable but known not to have died in the U.K. were excluded
from calculations.
1967 8(5M,3F)
1981 3
Deaths 4 1
(all proteinuric, Proteinuric Microalbuminuric
1990
1 renal
Deaths Proteinuric Microalbuminuric
(renal failure)
Fig. 1. Diagrammatic representation of the outcome of the 8 initially
microalbuminuric patients over a follow-up period of 23 years.
AER of 1038 .tg/min and serum creatinine of 97 prnol/liter. For
the remaining three patients still alive in this group, one was in
renal failure with creatinine of 222 mol/liter and was being
treated for hypertension (age 66 years; duration of diabetes 56
years; AER 898 jg/min). One patient (age 61 years; duration of
diabetes 36 years) remained microalbuminuric (AER:37.5 f1g/
mm) with a blood pressure of 150/85 mm Hg on no treatment
and a normal creatinine of 91 mol/liter. He exhibited back-
ground retinopathy and there were no red blood cells or casts in
his urine microscopy. The third patient (age 67 years; duration
of diabetes 37 years) who was proteinuric in 1981 (AER 652
j.g/min) went into acute renal failure in 1984 after receiving an
aminoglycoside antibiotic and required temporary hemodialysis
therapy. She reverted from overt proteinuria to microalbumin-
uria (AER 40.3 g/min) following antihypertensive treatment
and a low protein diet. Her serum creatinine was 97 mol/liter.
Thus in the microalbuminuric group after 23 years of follow-up,
the overall frequency of proteinuria, prior to the use of any
antihypertensive therapy which may have resulted in subse-
quent amelioration of urinary albumin excretion, was 87.5% (N
= 7). All cause mortality was 62.5% (N = 5) and cardiovascular
mortality was 50% (N = 4). Progression to renal failure had
occurred in two of the eight patients (25%).
Of the 50 originally normoalbuminuric patients alive in 1981,
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information was available on 48 patients for re-study in 1990
(Fig. 2). Twelve patients (7M, SF) had died (age 62.2 4.0
years; duration of diabetes 31.7 3.8 years; initial AER 4.98
and range of 4.5 to 12.8 g/min): one from hypoglycemia, four
of cancer, six from cardiovascular causes, of whom one was
documented as being persistently Albustix test positive in
severe cardiac failure and had a raised serum creatinine of 196
mol/1iter before death, and one from pneumonia who was
known to be persistently Albustix test positive, hypertensive
and in renal failure while alive (serum creatinine 389 mol/liter).
Of the 36 patients still alive [age 58.8 2.4 years; duration 29.8
1.2 years; initial AER 10.5 (0.4 to 21.8) pg/minI, two patients
were suffering from mental illness (senile dementia and depres-
sion) and were not formally assessed. Information from their
general practitioners revealed that these two patients (aged 81
and 56; duration of diabetes 44 and 24 years) had blood pressure
120/85 mm Hg and 156/76 mm Hg and serum creatinine of 106
and 109 prnol/liter, respectively. They were both known to be
Albustix test negative, Of the remaining 34 patients, one patient
considered proteinuric in 1981 (AER 146.2 .tg/min) reverted to
normoalbuminuria after starting on antihypertensive therapy
and a low protein diet. His serum creatinine was 101 mol/liter.
Another patient became hypertensive (BP 165/100 mm Hg) and
was documented as being persistently Albustix test positive
before starting treatment with an angiotensin converting en-
zyme inhibitor in 1986; in 1990 he had AER of 39.7 tg/min and
elevated creatinine of 200 mo1/liter. Five patients [aged 63.2
7.6; duration of diabetes 30.0 3.4 years; blood pressure 130
12.2/79.6 8.5 mm Hg; initial AER 2.34 (0.4 to 4.9) tg/min in
19671 had progressed to microalbuminuria since 1981 [AER 48.5
(38.1 to 71.0) sg/min] while maintaining normal renal function
(Sr 93.8 2.1 mol/liter). One of these five patients was
receiving treatment for Addison's disease and antihypertensive
medication; another patient had untreated hypertension (BP
190/100 mm Hg). Twenty-seven patients [aged 57.6 2.4;
duration of diabetes 30.2 1.1 years; initial AER 5.6 (1.5 to
20.3) g/min in 19671 remained normoalbuminuric with AER
8.16 (1.5 to 21.8) jg/min, creatinine of 98.2 3.4 imol/liter,
blood pressure 149.2 4.0/78.4 2.4 mm Hg in 1990. Among
these 27 patients three were treated for hypertension. Thus in
the normoalbuminuric group after 23 years follow-up the overall
frequency of clinical proteinuria was 9.4% (5 of 53), which was
significantly lower than that in the microalbuminuric group
(87.5%, 7 of 8) (relative risk 9.3, 95% C.!. 1.36 to 3.10, P <
0.05). Progression to renal failure occurred in 7.5% (4 of 53) of
initially normoalbuminuric patients, a proportion lower but not
significantly so than that in the microalbuminuric group 25% (2
of 8) (relative risk 3.31, 95% C.I. 0.72 to 15.24, NS). All cause
mortality was 32% (17 of 53), lower than that of the microalbu-
minuric patients (62.5%, 5 of 8) (relative risk 1.95, 95% C.!. 1.01
to 3.79) but not significantly so. Cardiovascular mortality was
significantly lower in the normoalbuminuric patients (17%, 9 of
53) compared to that of patients with microalbuminuria (50%, 4
of 8) (relative risk 2.94, 95% C.I. 1.18 to 7.34, P < 0.05). The
clinical outcome of the 61 patients after a 23 year follow-up is
summarized in Table 2. After adjusting for age and duration of
diabetes in a stepwise logistic regression analysis with cardio-
vascular death as the outcome variable, microalbuminuria
emerged as an independent significant predictor of cardiovas-
cular mortality (P = 0.047).
Discussion
This study which investigates the predictive power of mi-
croalbuminuria for clinical proteinuria, chronic renal failure and
mortality in insulin-dependent diabetes mellitus spans an obser-
vation period of 23 years. In 1982 we first reported that
insulin-dependent diabetic patients, with an overnight albumin
excretion rate between 30 and 140 ig/min, were approximately
20 times more likely to develop overt proteinuria than those
with albumin excretion rate below 30 j.g/min. In 1990 96% of
the patients still alive in 1981 were traced and reassessed. The
risk of progression to overt proteinuria remained significantly
increased in the microalbuminuria group. The risk of develop-
ing chronic renal failure as indicated by raised serum creatinine
was higher, but due to the small number of microalbuminuric
patients in the study, conventional statistical difference be-
tween the two groups was not achieved. One of the originally
microalbuminuric and two of the originally normoalbuminuric
1967 55(36M,19F)
1981 5 A
Deaths Normoalbuminuric Proteinuric
(1 proteinuric
in rena
1771990 2
U ntracea ble/"
2 Mental illness
einuric 28
Normoalbuminur-jc
6 Micrlbuminuric
12 Deaths
(2 proteinuric and
in renal failure)
Fig. 2. Diagrammatic representation of the
outcome of the 55 initially normoalbuminuric
patients over a follow-up period of 23 years.
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patients became overtly proteinuric prior to commencement on
antihypertensive or low-protein diet therapy with a subsequent
fall of their albumin excretion rates into the normal or microal-
buminuric range. Recent studies have shown that both antihy-
pertensive treatment [18, 19] and low protein diet [20, 21] are
effective in lowering albumin excretion rate in these patients
and preserving glomerular function by retarding the rate of
decline of glomerular filtration rate. The relative low frequency
of and delay in progression to renal failure in the microalbu-
minuric group is likely to be accounted for at least in part by
more effective treatment of hypertension in the last decade and
possibly by premature cardiovascular mortality. Only one of
the microalbuminuric patients remained persistently microalbu-
minuric without showing signs of progression to renal failure.
This patient at the age of 61 years had normal diastolic blood
pressure and systolic pressure only marginally elevated at 150
mm Hg. Recent observations suggest that the small proportion
of proteinuric insulin-dependent diabetic patients who maintain
untreated normal blood pressure are significantly less likely to
progress to end-stage renal failure than the patients who be-
come hypertensive [22].
Cardiovascular mortality was more than twice as high in the
microalbuminuric group independent of attained age and dura-
tion of diabetes. These mortality data in insulin-dependent
diabetic patients resemble observations made in microalbu-
minuric non-insulin-dependent diabetic patients [9—13] and in
the elderly non-diabetic patients [13, 14], and establish micro-
albuminuria as a powerful marker of risk of fatal cardiovascular
complications. In conclusion, this study, though in a relatively
small number of patients, supports the view that microalbumin-
uria is presently the most reliable early indicator available to
clinicians of adverse renal and cardiovascular events in diabetic
patients.
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